The purpose of this laboratory study was to assess the effect of povidone–iodine (PI) use topically on the conjunctiva in regard to needle bore contamination and to compare these results with our previous findings from an evaluation of bacterial contamination following gatifloxacin and moxifloxacin administration.
Methods:
We performed 100 conjunctival 27-gauge needle penetrations of both eyes of 13 fresh cadavers. Eyes were then soaked in 10% PI, after which conjunctiva was again penetrated 100 times. After conjunctival penetration, the needles were irrigated, and the irrigant was assessed for bacterial growth. Results were compared with previous work assessing fluoroquinolone effectiveness through the same model.
Results:
We observed a 28% (P = 0.003) decrease in bacterial growth and 40% (P < 0.0001) decrease in colony counts after PI placement. Differences between the effect of PI versus moxifloxacin and gatifloxacin were not statistically significant.
Conclusions:
There is a greater decrease in bacterial load after treatment with PI for surface cultures than for cultures obtained through a needle bore passed through the conjunctiva. PI is a superior approach to topical antibiotics to decrease conjunctival bacterial load.
Get full access to this article
View all access options for this article.
References
1.
SpeakerM.G., MilchF.A., ShahM.K., EisnerW., and KreiswirthB.N.Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology., 98:639–649, 1991; discussion 650.
2.
BannermanT.L., RhodenD.L., McAllisterS.K., MillerJ.M., and WilsonL.A.The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch. Ophthalmol., 115:357–361, 1997.
3.
MoshfeghiA.A., RosenfeldP.J., FlynnH.W.Jr., et al.Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina., 31:662–668, 2011.
4.
WenJ.C., McCannelC.A., MochonA.B., and GarnerO.B.Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch. Ophthalmol., 129:1551–1554, 2011.
5.
DiagoT., McCannelC.A., BakriS.J., et al.Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina., 29:601–605, 2009.
6.
AggioF.B., FarahM.E., de MeloG.B., et al.Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. Eye (Lond.)., 21:408–409, 2007.
7.
BhavsarA.R., IpM.S., and GlassmanA.R.The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am. J. Ophthalmol., 144:454–456, 2007.
8.
MoshfeghiD.M., KaiserP.K., ScottI.U., et al.Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol., 136:791–796, 2003.
9.
NelsonM.L., TennantM.T., SivalingamA., et al.Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina., 23:686–691, 2003.
10.
PilliS., KotsolisA., SpaideR.F., et al.Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am. J. Ophthalmol., 145:879–882, 2008.
11.
RothD.B., ChiehJ., SpirnM.J., et al.Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch. Ophthalmol., 121:1279–1282, 2003.
12.
WuL., Martinez-CastellanosM.A., Quiroz-MercadoH., et al.Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch. Clin. Exp. Ophthalmol., 246:81–87, 2008.
13.
SingermanL.J., MasonsonH., PatelM., et al.Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br. J. Ophthalmol., 92:1606–1611, 2008.
14.
BrownD.M., MichelsM., KaiserP.K., et al.Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology., 116:57–65.e55, 2009.
15.
FintakD.R., ShahG.K., BlinderK.J., et al.Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina., 28:1395–1399, 2008.
16.
KleinK.S., WalshM.K., HassanT.S., et al.Endophthalmitis after anti-VEGF injections. Ophthalmology., 116:1225.e1, 2009.
17.
JagerR.D., AielloL.P., PatelS.C., and CunninghamE.T.Jr.Risks of intravitreous injection: a comprehensive review. Retina., 24:676–698, 2004.
18.
CunninghamE.T.Jr., AdamisA.P., AltaweelM., et al.A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology., 112:1747–1757, 2005.
19.
HeierJ.S., AntoszykA.N., PavanP.R., et al.Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology., 113:633.e1–e4, 2006.
20.
TabanM., BehrensA., NewcombR.L., et al.Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch. Ophthalmol., 123:613–620, 2005.
21.
PetteyJ.H., MifflinM.D., KamaeK., et al.The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva. J. Ocul. Pharmacol. Ther., 29:450–455, 2013.
22.
MasonJ.O.3rd, WhiteM.F., FeistR.M., et al.Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina., 28:564–567, 2008.
23.
FriedmanD.A., MasonJ.O.3rd, EmondT., and McGwinG.Jr.Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina., 33:975–981, 2013.
24.
CiullaT.A., StarrM.B., and MasketS.Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology., 109:13–24, 2002.
25.
AptL., IsenbergS., YoshimoriR., and PaezJ.H.Chemical preparation of the eye in ophthalmic surgery. III. Effect of povidone-iodine on the conjunctiva. Arch. Ophthalmol., 102:728–729, 1984.
26.
SafarA., and DellimoreM.C.The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int. Ophthalmol., 27:307–312, 2007.
27.
InoueY., UsuiM., OhashiY., ShiotaH., and YamazakiT.Preoperative disinfection of the conjunctival sac with antibiotics and iodine compounds: a prospective randomized multicenter study. Jpn. J. Ophthalmol., 52:151–161, 2008.
28.
FergusonA.W., ScottJ.A., McGaviganJ., et al.Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study. Br. J. Ophthalmol., 87:163–167, 2003.
29.
Mino de KasparH., KreutzerT.C., Aguirre-RomoI., et al.A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora. Am. J. Ophthalmol., 145:136–142, 2008.
30.
CaldwellD.R., KastlP.R., CookJ., and SimonJ.Povidone-iodine: its efficacy as a preoperative conjunctival and periocular preparation. Ann. Ophthalmol., 16:577, 580, 1984.
31.
DereklisD.L., BufidisT.A., TsiakiriE.P., and PalassopoulosS.I.Preoperative ocular disinfection by the use of povidone-iodine 5%. Acta Ophthalmol. (Copenh.)., 72:627–630, 1994.
32.
GrimesS.R., MeinC.E., and TrevinoS.Preoperative antibiotic and povidone-iodine preparation of the eye. Ann. Ophthalmol., 23:263–266, 1991.
33.
IsenbergS.J., AptL., YoshimoriR., and KhwargS.Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch. Ophthalmol., 103:1340–1342, 1985.
34.
Mendivil SotoA., and MendivilM.P. The effect of topical povidone-iodine, intraocular vancomycin, or both on aqueous humor cultures at the time of cataract surgery. Am. J. Ophthalmol., 131:293–300, 2001.
35.
TaC.N., EgbertP.R., SinghK., ShriverE.M., et al.Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology., 109:2036–2040, 2002; discussion 2040–1.
36.
HaraJ., YasudaF., and HigashitsutsumiM.Preoperative disinfection of the conjunctival sac in cataract surgery. Ophthalmologica., 211(Suppl 1):62–67, 1997.
37.
BhavsarA.R., GoogeJ.M.Jr., StockdaleC.R., et al.Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch. Ophthalmol., 127:1581–1583, 2009.
38.
Green-SimmsA.E., EkdawiN.S., and BakriS.J.Survey of intravitreal injection techniques among retinal specialists in the United States. Am. J. Ophthalmol., 151:329–332, 2011.
39.
KimS.J., and TomaH.S.Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections. Ophthalmology., 118:1358–1363, 2011.
40.
YinV.T., WeisbrodD.J., EngK.T., et al.Antibiotic resistance of ocular surface flora with repeated use of a topical antibiotic after intravitreal injection. JAMA Ophthalmol., 131:456–461, 2013.
41.
MilderE., VanderJ., ShahC., and GargS.Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology., 119:1420–1424, 2012.
